Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, March 2007, p. 1089-1091, Vol. 51, No. 3
0066-4804/07/$08.00+0 doi:10.1128/AAC.00671-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Evaluation of Accessory Gene Regulator (agr) Group and Function in the Proclivity towards Vancomycin Intermediate Resistance in Staphylococcus aureus
Brian T. Tsuji,1,2,5
Michael J. Rybak,1,2,3*
Kerry L. Lau,1 and
George Sakoulas4
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences,1
School of Medicine, Wayne State University,3
Detroit Receiving Hospital and University Health Center, Detroit, Michigan 48201,2
Department of Medicine, Division of Infectious Diseases, New York Medical College, Munger Pavilion 245, Valhalla, New York, 10595,4
University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York 142605
Received 1 June 2006/
Returned for modification 15 August 2006/
Accepted 4 December 2006
Simulated therapeutic vancomycin exposures were evaluated against agr wild-type and knockout Staphylococcus aureus groups I, II, III, and IV using an in vitro pharmacodynamic model. All agr groups developed intermediate resistance to vancomycin after subtherapeutic exposure. The free unbound fraction of the area under the concentration-time curve (fAUC/MIC) required to suppress resistance was fourfold higher (P < 0.001) in agr dysfunctional strains (112 to 169) than that in parent wild-type strains (28).
* Corresponding author. Mailing address: Anti-Infective Research Laboratory, Pharmacy Practice - 4148, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201. Phone: (313) 993-4673. Fax: (313) 577-8915. E-mail:
m.rybak{at}wayne.edu.
Published ahead of print on 11 December 2006.
Antimicrobial Agents and Chemotherapy, March 2007, p. 1089-1091, Vol. 51, No. 3
0066-4804/07/$08.00+0 doi:10.1128/AAC.00671-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R. Jr., Craig, W., Billeter, M., Dalovisio, J. R., Levine, D. P.
(2009). Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm
66: 82-98
[Full Text]
-
Lodise, T. P., Lomaestro, B., Graves, J., Drusano, G. L.
(2008). Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity. Antimicrob. Agents Chemother.
52: 1330-1336
[Abstract]
[Full Text]
-
Tsuji, B. T., von Eiff, C., Kelchlin, P. A., Forrest, A., Smith, P. F.
(2008). Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype. Antimicrob. Agents Chemother.
52: 1533-1537
[Abstract]
[Full Text]
-
Rose, W. E., Rybak, M. J., Tsuji, B. T., Kaatz, G. W., Sakoulas, G.
(2007). Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. J Antimicrob Chemother
59: 1190-1193
[Abstract]
[Full Text]